View Older Stories
-
Citi Downgrades Merck (MRK) to Neutral
-
Citi Reiterates Buy Rating on Merck (MRK)
-
Merck to Participate in the Citi 2024 Global Healthcare Conference
-
Citi Reiterates Buy Rating on Exelixis (EXEL)
-
Merck (MRK) to Acquire EyeBio for Up to $3B
-
Merck to Acquire EyeBio
-
Midday movers: GameStop falls; Merck, Robinhood and Moderna rise
-
Top pharma stocks to own in 2024 – Citi
-
Citi Opens Upside Catalyst Watch on Merck (MRK)
-
This stock is a new preferred major pharma pick at Citi
-
Citi sees attractive buying opportunity in this beaten-down big pharma stock
-
Midday movers: Adobe, Moderna, and more
-
Merck to Participate in the Citi 18th Annual BioPharma Conference
-
Citi Reiterates Buy Rating on Merck (MRK) as Prometheus Acquisition is No Surprise, Potential to be a Great Deal
-
Merck (MRK) shares gain, Citi upgrades to buy as estimates ahead of consensus
-
Delta Air Lines, Amazon, Stellantis rise premarket; Harley-Davidson falls
-
Citi Upgrades Merck (MRK) to Buy on higher estimates
-
FedEx, Nvidia and Bumble rise premarket; First Republic, Credit Suisse fall
-
Today's most important upgrades
-
Citi Closes Catalyst Watch Merck (MRK)
-
Merck sees sharp decline in COVID sales for 2023 after strong fourth quarter
-
Pre-Open Stock Movers 11/29: (KRYS) (ADGI) (TWTR) Higher; (MRK) (UPS) Lower (more...)
-
2 Reasons Why Citi Downgraded Merck (MRK) to Neutral Today, Opened a Negative Catalyst Watch
-
UPDATE: Citi Downgrades Merck (MRK) to Neutral
-
Tech, health stocks rise, cyclicals fall on prospects of divided U.S. Congress
-
Merck to Present at the Citi 15th Annual BioPharma Virtual Conference
-
Merck (MRK) Prices $4.5 Billion Debt Offering
-
Merck Prices $4.5 Billion Debt Offering
-
S&P 500 rises on economic recovery and vaccine hopes, pulls back from highs
-
Wall St. falls as Apple, health shares drag, tariff deadline looms
-
Citi Reiterates Buy Rating on Novartis (NVS)
-
Elanco to become No.2 in animal health with $7.6 billion Bayer deal
-
Citi Bullish on Merck (MRK) MK-8591
-
S&P 500 Q4 2018 Buybacks Set 4th Consecutive Quarterly Record at $223 Billion; 2018 Sets Record $806 Billion
-
Bristol-Myers to buy Celgene for $74 billion in largest biopharma deal
-
Exclusive: Activist investor Elliott has stake in Germany's Bayer - sources
-
Merck to Present at the Citi 2018 Global Healthcare Conference
-
UPDATE: Citi Downgrades Eli Lilly (LLY) to Neutral
-
Merck (MRK) PT Raised to $84 at Citi
-
Merck (MRK) Added to Citi Recommended List, Bristol-Myers Squibb (BMY) Removed
-
Pre-Open Movers 10/22: (ARII) (DVAX) (PETS) Higher; (MRTX) (HAS) (BMY) Lower (more...)
-
Merck (MRK) PT Raised to $79 at Citi
-
Merck (MRK) PT Raised to $70 at Citi
-
Pre-Open Movers 04/23: (MDR) (VVC) (HSIC) Higher; (AKRX) (CBI) (AA) Lower (more...)
-
Wall Street rises but pares gains late after report of FBI raid
-
S&P 500 Q4 2017 Buybacks Rose 6.0% to $137.0 Billion; Full-Year 2017 Fell 3.2% to $519.4 Billion
-
Pre-Open Movers 01/16: (HAWK) (CATS) (MRK) Higher; (EIGR) (DPW) (KODK) Lower (more...)
-
Global stocks retreat from early gains as oil, copper lag
-
Merck (MRK) PT Lowered to $66 at Citi on 'Impact of the Delay for KEYNOTE 189 NSCLC Data'
-
Pre-Open Movers 10/30: (CAA) (ADMS) (DYN) Higher; (PSTI) (CTB) (CENX) Lower (more...)

